Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort
| Autor: | Satu K. Jyväkorpi, Annele Urtamo, Mika Kivimäki, Kari Luotola, Kaisu H. Pitkälä, Timo E. Strandberg |
|---|---|
| Přispěvatelé: | HUS Heart and Lung Center, Department of Medicine, Clinicum, Department of General Practice and Primary Health Care, HUS Helsinki and Uusimaa Hospital District, HUS Internal Medicine and Rehabilitation, Teachers' Academy |
| Rok vydání: | 2019 |
| Předmět: |
Male
Aging medicine.medical_specialty Statin medicine.drug_class Frail Elderly CARDIOVASCULAR DISEASE Nutritional Status 030204 cardiovascular system & hematology older people 03 medical and health sciences 0302 clinical medicine metabolic Interquartile range Surveys and Questionnaires Diabetes mellitus Internal medicine medicine Humans 030212 general & internal medicine Mortality OLDER-ADULTS Adverse effect PREALBUMIN Aged 80 and over 2. Zero hunger Frailty business.industry Hazard ratio cholesterol General Medicine TRANSTHYRETIN medicine.disease Confidence interval nutrition Phenotype Physical Fitness 3121 General medicine internal medicine and other clinical medicine Case-Control Studies Cohort Independent Living Hydroxymethylglutaryl-CoA Reductase Inhibitors Geriatrics and Gerontology PRIMARY PREVENTION business Body mass index Research Paper |
| Zdroj: | Age Ageing |
| ISSN: | 1468-2834 0002-0729 |
| Popis: | Background statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns. Methods in the Helsinki Businessmen Study, men born in 1919–34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued. Results we compared 259 current statin users (median age 82 years, interquartile range 80–85 years) with 266 non-users (83; 80–86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P Conclusions our study suggests that male octogenarian statin users preserved resilience and survival despite multimorbidity, and this may be associated with better nutritional status among statin users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|